BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Nov. 1, 2006
View Archived Issues
CAT's Humira Royalty Sold By AstraZeneca For $700M
LONDON - AstraZeneca plc, the new owner of Cambridge Antibody Technology Group (CAT) Ltd., sold the royalty rights to the antibody company's one marketed product, Humira, for $700 million. (BioWorld International)
Read More
Hold On Paion's Desmoteplase Lifted; Phase III Back On Track
Read More
Schizophrenia Gene Study Reveals Influence On Brain
Read More
Ethics Questions Delay Europe's Decision On Advanced Therapies
Read More
Cytheris' €24M Series B Round Should Fuel Company Into 2009
No Abstract
Read More
Innate Planning For IPO, Seeking €25M To €36M
No Abstract
Read More
LibraGen Enters Research Deal With Sanofi-Aventis
Read More
Renovo Reports Positive Data In Third Juvista Phase II Trial
Read More
Other News To Note
Read More